Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IBT-T03H
- Development stage
- Unknown
- Lead developer
- Integrated BioTherapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**IBT-T03H** is a monoclonal antibody developed for the treatment of Marburg virus disease (MVD) and Ravn virus infection, two closely related filoviruses causing severe hemorrhagic fever. It has demonstrated protective efficacy in preclinical animal models against both Marburg and Ravn viruses. The program received a $16.3 million contract from NIAID in 2021 to support formulation and process development, preclinical safety studies, manufacturing, and a planned Phase 1 first-in-human dose-ranging clinical trial, highlighting its potential as a medical countermeasure for emerging infectious disease threats.[1][2][4][8]
02
Targets
PYG (Glycogen phosphorylase)
Beyond the preview
Go deeper on IBT-T03H.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IBT-T03H.